Impact of Split Dosing the First Rituximab Infusion in Patients with High Lymphocyte Count

The most common adverse reactions to rituximab are infusion-related reactions (IRR). We evaluated the efficacy of split dosing the first rituximab infusion over two days to reduce IRR incidence in patients with hematological cancer and a high lymphocyte count. This is a retrospective observational s...

Descripción completa

Detalles Bibliográficos
Autores principales: Plante, Maude, Garneau, Laurence, Laprise-Lachance, Magali, Lemieux, Pierre, Dorval, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534443/
https://www.ncbi.nlm.nih.gov/pubmed/34677267
http://dx.doi.org/10.3390/curroncol28050349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534443/
https://www.ncbi.nlm.nih.gov/pubmed/34677267
http://dx.doi.org/10.3390/curroncol28050349

Ejemplares similares